Co-occurrence network analysis reveals the alterations of the skin microbiome and metabolome in adults with mild to moderate atopic dermatitis

Paulo Wender P. Gomes,Helena Mannochio-Russo,Junhong Mao,Haoqi Nina Zhao,Jacob Ancira,Craig D. Tipton,Pieter C. Dorrestein,Min Li
DOI: https://doi.org/10.1128/msystems.01119-23
2024-02-06
mSystems
Abstract:This study provides valuable insight into changes in the skin microbiome and associated metabolomic profiles in an adult population with mild to moderate atopic dermatitis. It also identifies new therapeutic targets that may be useful for developing personalized treatments for individuals with atopic dermatitis based on their unique skin microbiome and metabolic profiles.
microbiology
What problem does this paper attempt to address?
This paper aims to study the changes in the skin microbiome and metabolome of patients with mild to moderate atopic dermatitis (AD) and explore the differences between these changes and healthy skin. Specifically, the study compared skin samples from healthy adults, AD non-lesional areas (ADNL), and AD lesional areas (ADL) through 16S rRNA gene sequencing and mass spectrometry analysis. The study found that the skin microbial diversity of AD patients was significantly reduced, especially in the ADL area, while *Staphylococcus aureus* was significantly increased in AD patients. Metabolomic analysis showed significant differences in the distribution of metabolites between different groups, such as higher levels of dipeptide derivatives in the ADL area, which may be related to skin inflammation. Through co-occurrence network analysis, the study revealed differences in the co-occurrence patterns of microbes and metabolites between healthy ADNL and ADL. In ADL, *S. aureus* co-occurred with dipeptide derivatives, while in healthy and ADNL samples, certain commensal bacteria (such as *Paracoccus* sp., *Pseudomonas* sp., etc.) co-occurred with sphingolipid derivatives. These findings provide valuable insights into how AD affects the human skin microbiome and metabolome and identify new therapeutic targets, aiding in the development of personalized treatment methods tailored to the unique skin microbiome and metabolic characteristics of individuals.